Acasti Pharma Inc
XTSX:ACST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acasti Pharma Inc
Other
Acasti Pharma Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Acasti Pharma Inc
XTSX:ACST
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other
-$105m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Other
-CA$21.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-119%
|
CAGR 10-Years
-22%
|
|
|
Cronos Group Inc
TSX:CRON
|
Other
-$10.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-74%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other
-$522k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other
-CA$6.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-39%
|
|
Acasti Pharma Inc
Glance View
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The firm is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The firm's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The firm's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.
